Abstract
Two clinical studies have identified mutations affecting the EGF receptor in lung cancers from patients who respond robustly to gefitinib, a small-molecule inhibitor of the receptor tyrosine kinase. This work highlights the importance of conducting clinical trials with an eye to delivering molecule-targeted therapeutics to those patients most likely to benefit.
Original language | English (US) |
---|---|
Pages (from-to) | 577-578 |
Number of pages | 2 |
Journal | Nature medicine |
Volume | 10 |
Issue number | 6 |
DOIs | |
State | Published - Jun 2004 |
ASJC Scopus subject areas
- General Biochemistry, Genetics and Molecular Biology